SILK vs. ATRI, EMBC, KIDS, AORT, CATX, ATRC, FNA, SIBN, MDXG, and IRMD
Should you be buying Silk Road Medical stock or one of its competitors? The main competitors of Silk Road Medical include Atrion (ATRI), Embecta (EMBC), OrthoPediatrics (KIDS), Artivion (AORT), Perspective Therapeutics (CATX), AtriCure (ATRC), Paragon 28 (FNA), SI-BONE (SIBN), MiMedx Group (MDXG), and Iradimed (IRMD). These companies are all part of the "surgical & medical instruments" industry.
Atrion (NASDAQ:ATRI) and Silk Road Medical (NASDAQ:SILK) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations, dividends and community ranking.
Atrion received 39 more outperform votes than Silk Road Medical when rated by MarketBeat users. Likewise, 55.13% of users gave Atrion an outperform vote while only 50.56% of users gave Silk Road Medical an outperform vote.
Atrion has a net margin of 10.60% compared to Atrion's net margin of -29.02%. Silk Road Medical's return on equity of 7.75% beat Atrion's return on equity.
66.2% of Atrion shares are held by institutional investors. 22.8% of Atrion shares are held by insiders. Comparatively, 3.9% of Silk Road Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Silk Road Medical has a consensus target price of $20.10, indicating a potential downside of 5.85%. Given Atrion's higher probable upside, analysts plainly believe Silk Road Medical is more favorable than Atrion.
In the previous week, Atrion had 7 more articles in the media than Silk Road Medical. MarketBeat recorded 14 mentions for Atrion and 7 mentions for Silk Road Medical. Atrion's average media sentiment score of 1.07 beat Silk Road Medical's score of 0.45 indicating that Silk Road Medical is being referred to more favorably in the news media.
Atrion has higher earnings, but lower revenue than Silk Road Medical. Silk Road Medical is trading at a lower price-to-earnings ratio than Atrion, indicating that it is currently the more affordable of the two stocks.
Atrion has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500. Comparatively, Silk Road Medical has a beta of 1.43, suggesting that its share price is 43% more volatile than the S&P 500.
Summary
Atrion beats Silk Road Medical on 11 of the 17 factors compared between the two stocks.
Get Silk Road Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for SILK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SILK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Silk Road Medical Competitors List
Related Companies and Tools
